ATE292961T1 - Zur wirkstoffabgabe an zielorten im darm fähige zubereitung - Google Patents

Zur wirkstoffabgabe an zielorten im darm fähige zubereitung

Info

Publication number
ATE292961T1
ATE292961T1 AT99931535T AT99931535T ATE292961T1 AT E292961 T1 ATE292961 T1 AT E292961T1 AT 99931535 T AT99931535 T AT 99931535T AT 99931535 T AT99931535 T AT 99931535T AT E292961 T1 ATE292961 T1 AT E292961T1
Authority
AT
Austria
Prior art keywords
intestine
medicinal substance
site
preparation
intestinal
Prior art date
Application number
AT99931535T
Other languages
English (en)
Inventor
Takashi Ishibashi
Hiroaki Kubo
Hiroyuki Yoshino
Masakazu Mizobe
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Application granted granted Critical
Publication of ATE292961T1 publication Critical patent/ATE292961T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99931535T 1998-07-28 1999-07-26 Zur wirkstoffabgabe an zielorten im darm fähige zubereitung ATE292961T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21167898 1998-07-28
PCT/JP1999/003989 WO2000006128A1 (fr) 1998-07-28 1999-07-26 Preparation capable de liberer un medicament au niveau d'un site cible dans l'intestin

Publications (1)

Publication Number Publication Date
ATE292961T1 true ATE292961T1 (de) 2005-04-15

Family

ID=16609788

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99931535T ATE292961T1 (de) 1998-07-28 1999-07-26 Zur wirkstoffabgabe an zielorten im darm fähige zubereitung

Country Status (9)

Country Link
US (1) US6638534B1 (de)
EP (1) EP1101490B1 (de)
KR (1) KR100501022B1 (de)
CN (1) CN1163223C (de)
AT (1) ATE292961T1 (de)
AU (1) AU4800999A (de)
CA (1) CA2338780C (de)
DE (1) DE69924735T2 (de)
WO (1) WO2000006128A1 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
AU2002225763A1 (en) 2000-11-28 2002-06-11 Fmc Corporation Edible pga(propylene glycol alginate) coating composition
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ES2314227T7 (es) 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
WO2003084518A2 (fr) 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
US20030220351A1 (en) * 2002-05-24 2003-11-27 Gilbert Gonzales Enteric coated caffeine tablet
WO2004087109A1 (ja) * 2003-03-27 2004-10-14 Hisamitsu Pharmaceutical Co., Inc. 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
JP4771956B2 (ja) 2003-11-04 2011-09-14 スパーナス ファーマシューティカルズ インコーポレイテッド バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物
PT2210605T (pt) 2003-11-04 2017-04-24 Tcd Royalty Sub Llc Formas de dosagem única diária de tróspio
EP1691789B1 (de) 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol-freie base, salze, wasserfreie formen oder solvate davon, entsprechende pharmazeutische zusammensetzungen, formulierungen mit kontrollierter freisetzung und behandlungs- oder abgabeverfahren
AU2005209843B2 (en) 2004-01-30 2012-02-16 The Johns Hopkins University Nitroxyl progenitor compounds and methods of use
AT500144A1 (de) * 2004-03-05 2005-11-15 Sanochemia Pharmazeutika Ag Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung
AU2005237580B2 (en) * 2004-04-28 2011-06-16 Procarrier, Inc. Oral formulation for delivery of poorly absorbed drugs
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
EP2803357B1 (de) 2004-06-25 2020-11-18 The Johns-Hopkins University Angiogenesehemmer
FR2878159B1 (fr) * 2004-11-24 2008-10-17 Flamel Technologies Sa Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
BRPI0615972A2 (pt) 2005-07-29 2011-05-31 Concert Pharmaceuticals Inc composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto
US8912214B2 (en) * 2005-07-29 2014-12-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of Chk2 kinase inhibitors for cancer treatment
US20070154412A1 (en) * 2005-12-30 2007-07-05 Nolan Lee Phillips Dentifrices comprising biogenic silica materials
US20070154413A1 (en) * 2005-12-30 2007-07-05 Nolan Lee Phillips Dentifrices comprising biogenic silica materials
TW200808380A (en) * 2006-02-21 2008-02-16 Shinetsu Chemical Co Enteric-coated preparation for site-specific delivery of drug to site within the small intestine
SI2586435T1 (sl) 2006-03-17 2016-12-30 The Johns Hopkins University Derivati N-hidroksilsulfonamida kot novi fiziološko uporabni donorji nitroksila
CN101557828B (zh) 2006-07-19 2014-01-15 德克萨斯大学系统董事会 用于治疗炎性肠病的磷脂与含有5-氨基水杨酸之药物的制备物
US20080159968A1 (en) * 2006-12-27 2008-07-03 Fultz William C Dentifrices comprising biogenic silica materials and calcium carbonate
US20080159967A1 (en) * 2006-12-27 2008-07-03 Fultz William C Dentifrices comprising biogenic silica materials and at least one calcium phosphate
CA2675755C (en) 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine and pyridazine derivatives as kinase inhibitors
AU2008304200B2 (en) 2007-09-26 2013-12-19 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
ES2601192T3 (es) 2008-05-07 2017-02-14 Cardioxyl Pharmaceuticals Inc. Nuevos compuestos nitrosos como donadores de nitroxilo y métodos de uso de los mismos
JP5670325B2 (ja) 2008-06-19 2015-02-18 エックスカバリー ホールディング カンパニー エルエルシー キナーゼ阻害化合物としての置換されたピリダジンカルボキサミド化合物
ES2641471T3 (es) 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
EP2255794A1 (de) 2009-05-29 2010-12-01 H e x a l Aktiengesellschaft Magensaftresistenter Überzug
EP2459177A1 (de) * 2009-07-30 2012-06-06 Evonik Röhm GmbH Zusammensetzung aus einem anionischen polymer-material und dem salz einer gesättigten monocarbonsäure mit 6 bis 22 kohlenstoffatomen
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
CA2782110A1 (en) * 2009-12-07 2011-06-16 Johns Hopkins University N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives
EP2509942A2 (de) 2009-12-07 2012-10-17 Johns Hopkins University Bis-acylierte hydroxylaminderivate
WO2011143347A2 (en) 2010-05-11 2011-11-17 Sensient Colors Llc Film coating composition and methods of making and using the same
AU2011311814B2 (en) 2010-10-08 2016-12-22 Xcovery Holdings, Inc. Substituted pyridazine carboxamide compounds
EP2670387A1 (de) 2011-02-03 2013-12-11 Lupin Limited Pharmazeutische orale retard-zusammensetzungen aus bepotastin
KR102061537B1 (ko) 2011-10-17 2020-01-03 더 존스 홉킨스 유니버시티 Ｈｎｏ 공여체들로서의 하이드록실아민으로 치환된 멜드럼산, 바르비투르산 및 피라졸론 유도체들
BRPI1106900A2 (pt) * 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
CA2868362C (en) 2012-03-29 2018-07-31 Jerome Schentag Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
WO2013175500A1 (en) * 2012-04-23 2013-11-28 Cadila Healthcare Limited Delazed release pharmaceutical compositions of salsalate
EP2914579A1 (de) 2012-11-01 2015-09-09 The Johns Hopkins University Gesteuerte hno-freisetzung durch intramolekulare zyklisierungseliminierung
PT2945620T (pt) 2013-01-18 2018-02-21 Cardioxyl Pharmaceuticals Inc Dadores de nitroxilo com índice terapêutico melhorado
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
JP6702855B2 (ja) 2013-04-07 2020-06-03 ザ・ブロード・インスティテュート・インコーポレイテッド 個別化された新生物ワクチンの組成物及び方法
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN120695169A (zh) 2013-12-20 2025-09-26 博德研究所 使用新抗原疫苗的联合疗法
EP3126329B1 (de) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamid-nitroxyl-donatoren
FR3018689B1 (fr) * 2014-03-20 2017-04-28 Centre Hospitalier Univ De Clermont Ferrand Inhibiteurs de l'acetylcholinesterase d'action centrale pour la prevention et/ou le traitement des neuropathies chimio-induites et leurs symptomes, compositions, utilisations, methodes et trousse correspondantes.
US9682938B2 (en) 2014-05-27 2017-06-20 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2015183838A1 (en) 2014-05-27 2015-12-03 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
JP2018506514A (ja) 2014-12-23 2018-03-08 セレコー，インコーポレイテッド 化合物、組成物および方法
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
EP3297660A2 (de) 2015-05-20 2018-03-28 The Broad Institute Inc. Gemeinsam genutzte neoantigene
CA2986703A1 (en) 2015-06-09 2016-12-15 Rexahn Pharmaceuticals, Inc. Fluorocyclopentenylcytosine uses and processes of preparation
KR20180049015A (ko) 2015-09-04 2018-05-10 렉산 파마슈티컬스, 인코포레이티드 퀴녹살리닐-피페라진아미드의 사용 방법
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018067422A1 (en) 2016-10-03 2018-04-12 Congxin Liang Novel jak1 selective inhibitors and uses thereof
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3489222A1 (de) 2017-11-23 2019-05-29 medac Gesellschaft für klinische Spezialpräparate mbH Sulfasalazinesalze, herstellungsverfahren und verwendungen
FI3488868T3 (fi) 2017-11-23 2023-10-20 Medac Ges Fuer Klinische Spezialpraeparate Mbh Suun kautta annettava sulfasalatsiinia ja/tai sulfasalatsiinin orgaanista suolaa sisältävä farmaseuttinen koostumus, valmistusmenetelmä ja käyttö
WO2019211492A1 (en) 2018-05-04 2019-11-07 Tollys Tlr3 ligands that activate both epithelial and myeloid cells
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US12285401B2 (en) * 2019-04-04 2025-04-29 Daegu-Gyeongbuk Medical Innovation Foundation Pharmaceutical composition comprising trimebutine or pharmaceutically acceptable salt thereof as an active ingredient for prevention or treatment of cancer
EP3955923A1 (de) 2019-04-18 2022-02-23 The Regents Of The University Of Michigan Kombination mit checkpoint-inhibitoren zur behandlung von krebs
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
AU2020413225A1 (en) 2019-12-27 2022-06-23 Evelo Biosciences, Inc. Solid dosage forms containing bacteria and microbial extracellular vesicles
WO2021146523A1 (en) 2020-01-17 2021-07-22 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
US20230190831A1 (en) 2020-04-17 2023-06-22 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
CN116249774A (zh) 2020-05-26 2023-06-09 迪奥尼斯治疗公司 核酸人工微型蛋白质组文库
US20240050415A1 (en) 2020-06-05 2024-02-15 Henry Ford Health System Daclatasvir for use in treating lung and prostate cancer
MX2023003089A (es) 2020-09-18 2023-05-09 Evelo Biosciences Inc Formas farmaceuticas solidas de bacterias.
WO2022061123A1 (en) 2020-09-21 2022-03-24 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
AR123960A1 (es) 2020-10-29 2023-01-25 Evelo Biosciences Inc Composiciones que comprenden componentes de espirulina
US20240058271A1 (en) 2020-12-14 2024-02-22 Kevin Huynh Extracellular vesicle preparations
EP4267554A1 (de) 2020-12-22 2023-11-01 Mekanistic Therapeutics LLC Substituierte aminobenzylheteroarylverbindungen als egfr- und/oder pi3k-hemmer
EP4267154A1 (de) 2020-12-22 2023-11-01 Evelo Biosciences, Inc. Zusammensetzungen mit tierhämoglobin
WO2022164806A1 (en) 2021-01-26 2022-08-04 Evelo Biosciences, Inc. Prevotella extracellular vesicle preparations
US20240148797A1 (en) 2021-02-26 2024-05-09 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
WO2022187578A1 (en) 2021-03-05 2022-09-09 Evelo Biosciences, Inc. Solid dosage forms
WO2022189861A1 (en) 2021-03-08 2022-09-15 Tollys Carbohydrate conjugates of tlr3 ligands and uses thereof
JP2024516110A (ja) 2021-04-08 2024-04-12 エヴェロ バイオサイエンシズ，インコーポレーテッド 細菌を含有する医薬組成物
WO2022221183A1 (en) 2021-04-12 2022-10-20 Evelo Biosciences, Inc. Fournierella extracellular vesicle preparations
WO2022251166A2 (en) 2021-05-25 2022-12-01 Evelo Biosciences, Inc. Bacterial compositions comprising soy hemoglobin
US20240342169A1 (en) 2021-08-10 2024-10-17 Betta Pharmaceuticals Co., Ltd Use of ensartinib or salt thereof in treatment of disease carrying met 14 exon skipping mutation
WO2023049268A1 (en) 2021-09-24 2023-03-30 Evelo Biosciences, Inc. Solid dosage forms containing bacteria and microbial extracellular vesicles
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
WO2023114300A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Fournierella massiliensis bacteria extracellular vesicle preparations
WO2023114293A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Extracellular vesicle assays
WO2023114295A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Veillonella parvula bacteria extracellular vesicle preparations
WO2023146843A1 (en) 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023183396A1 (en) 2022-03-22 2023-09-28 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023200837A1 (en) 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023239728A1 (en) 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles
WO2024102226A1 (en) 2022-10-14 2024-05-16 Evelo Biosciences, Inc. Methods for assaying drug substances and drug products by using cell lines with nf-kb- inducible reporter genes
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
WO2025101914A1 (en) 2023-11-10 2025-05-15 Mekanistic Therapeutics Llc Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors having improved therapeutic index against solid tumors
WO2025126109A1 (en) 2023-12-15 2025-06-19 Ensem Therapeutics, Inc. Anilino-pyrazole derivatives, compositions and methods thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
WO1981002671A1 (en) 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
ATE14379T1 (de) * 1981-04-27 1985-08-15 Haessle Ab Pharmazeutisches praeparat.
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4755387A (en) * 1985-03-21 1988-07-05 The Procter & Gamble Company Therapeutic particles
DE69011618T2 (de) 1989-05-11 1994-12-15 Chugai Pharmaceutical Co Ltd Mundzubereitung zur verabreichung an bestimmter stelle des darmes.
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH06256166A (ja) 1993-01-06 1994-09-13 ▲寛▼治 ▲高▼田 薬物放出制御製剤
JPH072650A (ja) * 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd 放出部位制御型製剤
JP2917799B2 (ja) 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
JPH08143476A (ja) 1994-11-18 1996-06-04 Japan Tobacco Inc 薬物放出制御膜及び固形製剤
JPH10120571A (ja) 1996-10-22 1998-05-12 Sato Yakuhin Kogyo Kk 塩酸ジルチアゼム徐放性製剤
JP3047325B2 (ja) * 1997-01-07 2000-05-29 謙二 徳永 品質劣化を抑制したローヤルゼリー錠剤の製造方法

Also Published As

Publication number Publication date
DE69924735T2 (de) 2006-01-19
CA2338780C (en) 2007-01-02
KR20010074757A (ko) 2001-08-09
EP1101490A4 (de) 2002-04-03
CN1311667A (zh) 2001-09-05
AU4800999A (en) 2000-02-21
US6638534B1 (en) 2003-10-28
EP1101490B1 (de) 2005-04-13
KR100501022B1 (ko) 2005-07-18
WO2000006128A1 (fr) 2000-02-10
DE69924735D1 (de) 2005-05-19
CN1163223C (zh) 2004-08-25
CA2338780A1 (en) 2000-02-10
EP1101490A1 (de) 2001-05-23

Similar Documents

Publication Publication Date Title
ATE292961T1 (de) Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
KR0138651B1 (ko) 치아질환을 경감시키는데 유용한 개선된 상분리-미소봉입된 제약학적 조성물
ATE285228T1 (de) Arzneistoffverabreichungsystem zur verzögerten, völlstandigen wirkstoffabgabe im verdauungstrakt
ATE260649T1 (de) Pharmazeutische formulierung und dosierform bestehend aus polysacchariden zur kontrollierten wirkstoff-freisetzung im dickdarm
ATE225165T1 (de) Im unteren teil des verdauungstrakts freisetzende pharmazeutische zubereitung in form einer beschichteten kapsel
IL161628A0 (en) Pharmaceutical dosage form with multiple coatings
EP0673645A3 (de) Arzneimittel.
ATE213936T1 (de) Pharmazeutische dosisform mit mehrfacher darmlöslicher polymerbeschichtung zur wirkstoffabgabe im kolon
ATE193439T1 (de) Kontrolliertes pharmazeutisches präparat zur gezielten freisetzung eines medizinischen wirkstoffes im intestinaltrakt
KR880013586A (ko) 고체상태성질을 가진 제거 가능한 기질을 포함하는 투약기
BR9914384A (pt) Dispositivo e método para liberação de um agente ativo em aerossol aos pulmões de um paciente humano
CA2359812A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
IL118240A (en) Oral coated capsule dosage form of omega-3 polyunsaturated acid for release of the acid in the intestine
DE60124285D1 (de) Beschichtete medizinische geräte
PT96921B (pt) Dispositivo de libertacao intermitente
DE60035421D1 (de) Chitosanpulver enthaltende feste zubereitungen und verfahren zu deren herstellung
FR2845289B1 (fr) Spheroides, procede de preparation et compositions pharmaceutiques.
AU6886987A (en) Veterinary compositions incorporating a water swellable polymer
MA21895A1 (fr) Association de vitamine "a" a dose physiologique et differents principes actifs .
GB9815801D0 (en) Liquid polymeric compositions for controlled released bioactive substances
Gol'dberg et al. Acute toxicity of carminomycin administered perorally to laboratory animals
BR9809552A (pt) Dispositivo transuretral para distribuição de um medicamento para a uretra de um corpo humano ou animal, processo para incorporar um medicamento em um dispositivo transuretral, e, utilização de um dispositivo transuretal.
IT1244867B (it) Forma farmaceutica a rilascio rapido ritardato
TH13953A (th) ฟิล์มตัวนำส่งยาใช้เฉพาะที่ในการบำบัดโรคปริทันต์
BG104064A (en) Medicamentous form with controlled release of poorly soluble basic medicamentous forms

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties